General Information of Drug (ID: DMUJ18P)

Drug Name
N-methyl-1-(2-thiophen-2-ylphenyl)methanamine Drug Info
Synonyms
N-Methyl-N-(2-thien-2-ylbenzyl)amine; 852180-66-6; N-methyl-1-(2-thiophen-2-ylphenyl)methanamine; CHEMBL549343; N-Methyl-2-thien-2-ylbenzylamine; N-methyl-1-(2-(thiophen-2-yl)phenyl)methanamine; AC1OEOYY; CTK5F4550; DTXSID00427632; MolPort-000-143-044; HMS3604E04; ZINC3880928; SBB093177; BDBM50294171; AKOS010337666; RP04434; DB07196; n-methyl-n-(2-thiophen-2-ylbenzyl)amine; methyl[(2-(2-thienyl)phenyl)methyl]amine; KB-204244; KB-302285; RT-014485; Benzenemethanamine,N-methyl-2-(2-thienyl)-; Y4269; Benzenemethanamine, N-methyl-2-(2
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
7060565
CAS Number
CAS 852180-66-6
TTD Drug ID
DMUJ18P

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Discontinued Drug(s)
Investigative Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Bestatin DM8L9D4 Acute myeloid leukaemia 2A60 Approved [2]
LYS006 DMI17QR Ulcerative colitis DD71 Phase 2 [3]
Acebilustat DM19UTO Chronic blistering skin disorder ME63.3 Phase 1 [4]
DG051 DM3I0GS Myocardial infarction BA41-BA43 Discontinued in Phase 2 [5]
Acetate Ion DMD08RH Discovery agent N.A. Investigative [6]
JNJ-10392980 DMZH0K8 Discovery agent N.A. Investigative [7]
4-(2-amino-1,3-thiazol-4-yl)phenol DMH5CAQ Discovery agent N.A. Investigative [1]
2-(4-phenoxyphenoxy)ethanamine DM7TBUJ Discovery agent N.A. Investigative [8]
3-(Benzyloxy)Pyridin-2-Amine DM35VEI Discovery agent N.A. Investigative [6]
2-(7-(benzyloxy)-1H-indol-3-yl)ethanamine DMD2QVO Discovery agent N.A. Investigative [9]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Leukotriene A-4 hydrolase (LTA4H) TTXZEAJ LKHA4_HUMAN Inhibitor [1]

References

1 The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
2 DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41.
3 Discovery of LYS006, a Potent and Highly Selective Inhibitor of Leukotriene A(4) Hydrolase. J Med Chem. 2021 Feb 25;64(4):1889-1903.
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5 BAY x 1005 attenuates atherosclerosis in apoE/LDLR - double knockout mice. J Physiol Pharmacol. 2007 Sep;58(3):583-8.
6 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
7 Identification of a potent, selective, and orally active leukotriene a4 hydrolase inhibitor with anti-inflammatory activity. J Med Chem. 2008 Jul 24;51(14):4150-69.
8 Activation and inhibition of leukotriene A4 hydrolase aminopeptidase activity by diphenyl ether and derivatives. Bioorg Med Chem Lett. 2008 Dec 15;18(24):6549-52.
9 Discovery of multitarget inhibitors by combining molecular docking with common pharmacophore matching. J Med Chem. 2008 Dec 25;51(24):7882-8.